Company news

Ani Pharmaceuticals, Inc. (NASDAQ:ANIP) news

Ani Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 30, 2026: ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be…

Ani Pharmaceuticals, Inc. (NASDAQ:ANIP) news

Press releases & updates

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

ANI Pharmaceuticals to Present at September Investor Conferences

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

ANI Pharmaceuticals Announces Board Transition

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity